MERCK CRIXIVAN SUPPLY WILL REACH 350,000 KG IN 1998; COZAAR/HYZAAR HAVE 2% SHAREOF ANTIHYPERTENSIVE/HEART FAILURE MARKET, COMPANY TELLS ANALYSTS
Executive Summary
The protease inhibitor Crixivan has been used by over 70,000 people in the U.S., up from 50,000 in mid-September, according to data from the primary distributor Stadtlanders. Merck presented the Crixivan figures at a Dec. 18 securities analysts meeting at the company's Whitehouse Station, N.J. headquarters.